Drug intelligence / Profile preview

regorafenib + TAS-102-Agen Biomedical-deep vein thrombosis

Development stage: Phase 2
Lead developer: Agen Biomedical
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

This entry refers to **ThromboView** (also known as DI-8001), a radiopharmaceutical diagnostic imaging agent developed by **Agen Biomedical** (a subsidiary of Agenix) for the detection of **deep vein thrombosis** (DVT) and pulmonary embolism (PE). The input name appears to be a composite string incorrectly combining the oncology drug combination "regorafenib + TAS-102" with the developer and indication for ThromboView. ThromboView consists of a humanized monoclonal antibody fragment (Fab') that specifically targets a neo-epitope on **activated platelets** involved in active clot formation. When labeled with Technetium-99m (99mTc), it allows for the visualization of fresh thrombi using SPECT (Single Photon Emission Computed Tomography) imaging. It has been evaluated in Phase II clinical trials for its diagnostic accuracy in detecting initial or recurrent DVT compared to traditional venography, offering a potentially more accurate and less invasive diagnostic alternative.

Brand names: ThromboView
Other names: 99mTc-labeled humanized monoclonal antibody fragment Fab'Technetium (99mTc) humanized monoclonal antibody fragment Fab'

Beyond the preview

Go deeper on regorafenib + TAS-102-Agen Biomedical-deep vein thrombosis.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on regorafenib + TAS-102-Agen Biomedical-deep vein thrombosis.

Explore the full profile